Targeting PI3K/Akt signaling in prostate cancer therapy
M Hashemi, A Taheriazam, P Daneii… - Journal of Cell …, 2023 - Springer
Urological cancers have obtained much attention in recent years due to their mortality and
morbidity. The most common and malignant tumor of urological cancers is prostate cancer …
morbidity. The most common and malignant tumor of urological cancers is prostate cancer …
Targeting PI3K/Akt signaling in prostate cancer therapy.
M Hashemi, A Taheriazam, P Daneii… - Journal of Cell …, 2022 - europepmc.org
Urological cancers have obtained much attention in recent years due to their mortality and
morbidity. The most common and malignant tumor of urological cancers is prostate cancer …
morbidity. The most common and malignant tumor of urological cancers is prostate cancer …
Targeting PI3K/Akt signaling in prostate cancer therapy
M Hashemi, A Taheriazam, P Daneii… - Journal of cell …, 2023 - pubmed.ncbi.nlm.nih.gov
Urological cancers have obtained much attention in recent years due to their mortality and
morbidity. The most common and malignant tumor of urological cancers is prostate cancer …
morbidity. The most common and malignant tumor of urological cancers is prostate cancer …
[引用][C] Targeting PI3K/Akt signaling in prostate cancer therapy
M Hashemi, A Taheriazam, P Daneii… - Journal of Cell …, 2022 - cir.nii.ac.jp
Targeting PI3K/Akt signaling in prostate cancer therapy | CiNii Research CiNii 国立情報学
研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …
研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …
[HTML][HTML] Targeting PI3K/Akt signaling in prostate cancer therapy
M Hashemi, A Taheriazam, P Daneii… - Journal of Cell …, 2023 - ncbi.nlm.nih.gov
Urological cancers have obtained much attention in recent years due to their mortality and
morbidity. The most common and malignant tumor of urological cancers is prostate cancer …
morbidity. The most common and malignant tumor of urological cancers is prostate cancer …
Targeting PI3K/Akt signaling in prostate cancer therapy
M Hashemi, A Taheriazam, P Daneii… - Journal of Cell …, 2023 - Wiley Online Library
Urological cancers have obtained much attention in recent years due to their mortality and
morbidity. The most common and malignant tumor of urological cancers is prostate cancer …
morbidity. The most common and malignant tumor of urological cancers is prostate cancer …
Targeting PI3K/Akt signaling in prostate cancer therapy.
M Hashemi, A Taheriazam, P Daneii… - Journal of Cell …, 2022 - europepmc.org
Urological cancers have obtained much attention in recent years due to their mortality and
morbidity. The most common and malignant tumor of urological cancers is prostate cancer …
morbidity. The most common and malignant tumor of urological cancers is prostate cancer …